The Patent-Powered Proposal: A Strategic Guide for Academic Researchers to Secure Grant Funding
“Research is seeing what everybody else has seen and thinking what nobody else has thought.” — Albert Szent-Györgyi 1 Introduction: […]
December 2025
The New Prescription for IP: A Strategic Guide to Patenting AI-Derived Drugs
Artificial Intelligence (AI) is no longer a futuristic buzzword confined to academic papers; it is a powerful, active engine of
The New Prescription for IP: A Strategic Guide to Patenting AI-Derived Drugs Read Post »
Navigating the Maze: A Guide to European SPCs for Generic Drug Planners
Introduction: The €1 Billion Chess Game – Why SPCs are the Endgame for European Generic Market Entry In the high-stakes
Navigating the Maze: A Guide to European SPCs for Generic Drug Planners Read Post »
The Uncoupling of Device and Drug: A Strategic Post-Mortem of Teva v. Amneal and the New Era of Orange Book Rigor
1. Executive Summary: The End of the “Device Thicket” Era For nearly two decades, the pharmaceutical industry has operated under
Navigating the New IP Frontier for AI-Discovered Drugs
We stand at the precipice of a revolution in pharmaceutical research, a paradigm shift driven not by a new molecule
Navigating the New IP Frontier for AI-Discovered Drugs Read Post »
The Billion-Dollar Blind Spot: Why Traditional Drug Spend Forecasts Fail and How Patent Data Provides the Missing Link
Introduction: The High Cost of Inaccuracy In the high-stakes world of pharmaceutical finance and healthcare planning, the ability to accurately
How Regulatory Affairs Masters Patent Intelligence to Architect Pharmaceutical Success
Part I: The Strategic Evolution of Regulatory Affairs in an IP-Driven Landscape In the high-stakes, capital-intensive world of pharmaceutical development,
How Regulatory Affairs Masters Patent Intelligence to Architect Pharmaceutical Success Read Post »
A Pharma Exec’s Guide to Preliminary Freedom-to-Operate Analysis
The complete strategic and technical guide to pharmaceutical Freedom-to-Operate analysis: patent thicket architecture, Paragraph IV litigation dynamics, biosimilar entry strategy,
A Pharma Exec’s Guide to Preliminary Freedom-to-Operate Analysis Read Post »
Navigating and De-Risking the Pharmaceutical R&D Portfolio
The Billion-Dollar Gamble: Confronting the Unforgiving Realities of Pharma R&D In the world of biopharmaceutical research and development, we operate
Navigating and De-Risking the Pharmaceutical R&D Portfolio Read Post »
